GSA Capital Partners’s INmune Bio INMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$405K Buy
207,602
+125,611
+153% +$258K 0.02% 1201
2026
Q2
$134K Buy
+81,991
New +$113K 0.01% 1597

Other funds holding INMB

GSA Capital Partners's INMB Position: Q3 2026 in Review

GSA Capital Partners increased its INmune Bio (INMB) stake by 153% in Q3 2026, buying an estimated $258K and bringing the position to 207,602 shares worth $405K. The position accounts for 0.02% of the portfolio, ranked #1201.

GSA Capital Partners first reported a position in INMB in Q2 2026 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

  • GSA Capital Partners held 207,602 shares of INmune Bio worth $405K as of Q3 2026.
  • GSA Capital Partners bought 125,611 INmune Bio shares in Q3 2026, an estimated $258K.
  • INmune Bio made up 0.02% of GSA Capital Partners's portfolio in Q3 2026, its #1201 holding.
  • GSA Capital Partners first reported a position in INmune Bio in Q2 2026 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.